A recent Phase 3 clinical trial demonstrated that first-line durvalumab (a programmed death-ligand 1 (PDL-1) inhibitor) in combination with platinum-etoposid significantly improved OS was observed in patients with ES-SCLC treated with the combination regimen compared to platinum-etoposide alone, and the mOS was 12.9 months versus 10.5 months, respectively. Here, CD274 is linked to small cell lung carcinoma.